Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-09-27

FDA Approved: VOSEVI — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) from Gilead Sciences, Inc. VOSEVI is a fixed-dose combination…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VOSEVI (sofosbuvir/velpatasvir/voxilaprevir)

Snippet

SUPPL AP for VOSEVI (SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR)